Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory

Executive Summary

• Rapid Dose Therapeutics announced a suite of strategic milestones in 2026, including an Indian patent grant for its nicotine bilayer oral film and regulatory approval to launch its QuickStrip™ medical cannabis product in Brazil.
• The company highlighted ongoing PK trials with a major global tobacco partner, expanded U.S. market visibility via an OTCQB listing, and reported progress on a CBD bioavailability study funded by the NFL.
• These developments underscore RDT’s international IP growth, regulatory successes, and continued clinical validation, positioning it for broader commercialization across pharmaceutical, nutraceutical, nicotine, and wellness markets.

Key Details

• India Patent Grant: Secured Indian Patent No. IN 582202 for the Nicotine Bilayer Oral Film in partnership with Aavishkar Oral Strips Pvt. Ltd., enhancing IP coverage under the PCT framework (potential protection in 158 jurisdictions).
• Brazil Launch: Received ANVISA approval and launched QuickStrip™ medical cannabis product, providing entry into Brazil’s large pharmaceutical/healthcare market.
• Global Tobacco Collaboration: Ongoing fourth‑year PK trials with a major tobacco partner to demonstrate QuickStrip™ nicotine’s rapid absorption comparable to cigarettes.
• U.S. Market Presence: Listed on the OTCQB Venture Market under ticker RDTCF, improving liquidity and investor access in the United States.
• Clinical Research Progress: Conducting a CBD bioavailability study with University of Regina & University of Saskatchewan; over 60 % participant data collected; research funded by the NFL.
• Strategic Priorities for 2026:
• Expand regulated international markets via partnerships.
• Strengthen distribution channels for natural health products.
• Advance clinical research across multiple verticals.
• Scale Canadian manufacturing capabilities to pharmaceutical‑grade production.

Notable Quotes

“Our momentum in 2026 reflects the strength of our strategy and the scalability of the QuickStrip™ platform,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “With a resilient operating model and continued progress across IP, clinical development, and global markets, RDT is well insulated from current macroeconomic pressures and exceptionally well positioned to deliver sustainable, long‑term value for our shareholders.”